CI & Patent News: 23/11/2010

1) Paragraph IV Litigation:

1) Daiichi Sankyo & Genzyme Vs Impax & Glenmark Pharma

Product: Colesevelam; Complaint No: 1:10-cv-00997-UNA. Genzyme has sued only on two product patents mentioned below

Patent No Expiry Title
Dec 10, 2014 Amine polymer sequestrant and method of    cholesterol depletion
by Mandeville, III et. al.; USPC #424/78.12;
prosecuted by Hamilton, Brook, Smith & Reynolds, P.C. 
Jun 2, 2015 Alkylated amine polymers
by Mandeville, III et. al.; USPC #514/742;
prosecuted by Hamilton, Brook, Smith & Reynolds, P.C.

Impax is First to file and Subsequent ANDA filer is Glenmark.

2) Abbott Vs Roxane Laboratories (View on PriorSmart)


Jun 24, 2014 19-nor-vitamin D compounds
by DeLuca et. al.; USPC #552/653;
prosecuted by Andrus, Sceales, Starke & Sawall

3) Regeneron Pharma. v. Genentech (View on PriorSmart)

Drug generic names: Aflibercept & Ranibizumab

Declaratory judgement for non-infringement of certain patents (6897294; 6100071; 7771721; 6383486; 7374757; 5952199)

Facts: Roche markets LUCENTIS (Ranibizumab injection) in USA for wet age-related macular degeneration and Genetech is assignee of above said patents, and  Genetech is now part of Roche.  Regeneron Pharma with bayer (Bayer Press release), developed a VEGF Trap (Aflibercept ophthalmic solution) for the same indication of Ranibizumab injection. Regeneron expects that Genetech may sue Regeneron, if it launches VEGP Trap.

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s